A Look at the Latest Occurrences in the Biotechnology Sector: Special Research on China Biologic Products, Compugen, Curis, CytRx, and DBV Technologies
NEW YORK, February 16, 2015 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Moments ago, Analysts Review released new research updates concerning several important developing situations including China Biologic Products (NASDAQ: CBPO), Compugen (NASDAQ: CGEN), Curis (NASADQ: CRIS), CytRx (NASDAQ: CYTR), and DBV Technologies (NASDAQ: DBVT). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
To access our full PDF reports on a complementary basis, please visit the links below.
--
Today's update concerns the following companies:
============
Full PDF Download Links (you may have to copy and paste the following links into your browser):
CBPO Research Report: ( http://get.analystsreview.com/pdf/?c=China%20Biologic%20Products%20&d=16-Feb-2015&s=CBPO ),
CGEN Research Report: ( http://get.analystsreview.com/pdf/?c=Compugen&d=16-Feb-2015&s=CGEN )
CRIS Research Report: ( http://get.analystsreview.com/pdf/?c=Curis&d=16-Feb-2015&s=CRIS),
CYTR Research Report: ( http://get.analystsreview.com/pdf/?c=CytRx&d=16-Feb-2015&s=CYTR ),
DBVT Research Report: ( http://get.analystsreview.com/pdf/?c=DBV%20Technologies&d=16-Feb-2015&s=DCVT).
============
--
Analyst Update: Certifications, Upcoming Presentations, Agreements, and Affirmative Study Results
Reviewed by: Rohit Tuli, CFA®
The U.S. stocks closed higher on Friday with S&P 500 hitting an intraday record and the Dow Jones Industrial Average reaching its highest point so far this year. The Dow industrials added 46.97 points, or 0.26%, to 18019.35. The S&P 500 rose 8.51 points, or 0.41%, to 2096.99, and the Nasdaq Composite gained 36.22 points, or 0.75%, to 4893.84. The markets got a boost on hopes of a deal between Greece and its creditors. The continued redound in oil prices as well as strong economic data out of Europe also helped the markets in the rally. European markets also rose, driven by the Friday release of German data that showed the country's economy had grown in 2014's fourth quarter at a better-than-expected rate. Asia stocks mostly closed higher on Friday, following a global advance overnight, supported by reports of a new cease-fire agreement between Russia and Ukraine, Sweden's surprise move to cut its main rate into negative territory, and Greece agreeing to talks over its debt problems.
China Biologic Products, Inc.'s (China Biologic) subsidiary, Shandong Taibang Biological Products Co. Ltd., has received Good Manufacturing Practices ("GMP") certification from the China Food and Drug Administration (the "CFDA") for its new coagulation factor production facility.
Compugen Ltd.'s (Compugen) Principal Scientist, Ofer Levy, PhD, to deliver a presentation titled "Computational Discovery and Experimental Validation of Novel Players in the Immuno-Oncology Arena" on February 16, 2015 at the Onco-Immunology Meeting: Prospects of Immunity for Precision Cancer Medicine, to be held the Israel Institute of Advanced Studies, in Jerusalem, Israel.
Curis, Inc. (Curis) along with Aurigene Discovery Technologies Limited entered into an exclusive collaboration agreement focused on immuno-oncology and selected precision oncology targets. The collaboration provides for inclusion of multiple programs, with Curis having the option to exclusively license compounds once a development candidate is nominated within each respective program.
CytRx Corporation (CytRx) has announced encouraging Overall Survival (OS) results, the secondary endpoint, from its completed multicenter, randomized, open-label global Phase 2b clinical trial ivestigating the efficacy and safety of Aldoxorubicin compared with doxorubicin in subjects with soft tissue sarcomas (STS).
DBV Technologies S.A. (DBV Technologies) announced that six abstracts on Epicutanous Immunotherapy (EPIT®) were selected for presentation at the 2015 American Academy of Allergy, Asthma & Immunology Annual Meeting in Houston, Texas, to be held from February 20-24, 2015. The presentations will include detailed results from the Phase 2b trial of the Company's Viaskin® Peanut, as well as key preclinical data on EPIT's mechanism of action.
--
About Analysts Review
At Analysts Review, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
Analysts Review was designed for investors. By providing the best information available, we have set ourselves apart as one of the premier online investor communities.
--
Editor Note: This is not company news. We are an independent source and our views do not reflect the companies mentioned.
Compliance Procedure: Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA®. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
Further Resources: For more information about this release including editorial notes, compliance procedures and legal disclosures, please visit: http://www.analystsreview.com/editors
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article